Stoke Therapeutics: A Long-Term Biotech Growth Play - Why I Assign A Hold Rating (STOK)

Stoke Therapeutics, Inc. (NASDAQ: STOK ) stock is enjoying a great year. The past 6 months saw its stock gaining over 180%. Such gains could be already pricing in Phase 3 success of its lead pipeline. The company isn't just developing a drug butGamu Dave Innocent Pasi is a seasoned financial professional and writer, bringing a wealth of experience from his prior roles as a financial analyst and in investment research. With a strong background in analyzing financial statements, capital markets, and the macro ...